Oncology lead development in promising gene therapy pipeline; Report

24 September 2015

Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development across all stages.

However, the majority of these remain in early steps of development, with 76% at either the discovery or preclinical stage, according to business intelligence provider GBI Research.

The company’s latest report states that oncology, infectious diseases, genetic disorders, cardiovascular diseases and ophthalmological indications are the most active pipeline sectors, as well as the most widely studied in terms of the number of clinical trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK